Table 2 Patient characteristics. The clinical and pathological information about 286 patients in this study.

From: Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma

 

All patients (n = 286)

Age (y) (median (range))

65 (24–89)

Sex, n (%)

 Male

203 (71.0)

 Female

83 (29.0)

Surgical form, n (%)

 Nephrectomy

190 (66.4)

 Partial nephrectomy

96 (33.6)

Pathological stage, n (%)

 I

181 (63.3)

 II

16 (5.6)

 III

86 (30.1)

 IV

3 (1.0)

Histology, n (%)

 Clear cell renal cell carcinoma

279 (97.6)

 Clear cell renal cell carcinoma with sarcomatoid change

7 (2.4)

WHO/ISUP grade, n (%)

 1

34 (11.9)

 2

170 (59.4)

 3

54 (18.9)

 4

28 (9.8)

Necrosis, n (%)

 Present

69 (24.1)

 Absent

217 (75.9)

Outcome, n (%)

 Neither metastasis nor recurrence

190 (66.4)

 Alive with metastasis or recurrence

42 (14.7)

 Death from cancer

49 (17.1)

 Death from other causes

5 (1.7)

 Follow-up term (days) (median (range))

1572 (13 - 5323)